# Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07057791/  
OnCo record `nct07057791` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by PrECOG, LLC., now recruiting.

## Summary

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07057791 by PrECOG, LLC., with a registry enrolment figure of 60 participants, started 2026-03-30 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab 10 mg/kg; Ivonescimab 20 mg/kg. Conditions listed: Extensive Stage Lung Small Cell Cancer. Primary outcome: Optimal Dose of Ivonescimab in Combination with Carboplatin and Etoposide - Overall Response Rate (ORR); Optimal Dose of Ivonescimab in Combination with Carboplatin and Etoposide - Grade 3-5 Treatment-Related Toxicity Rate. Lung eligibility wording from the registry: "* Patients must have pathologically confirmed Extensive Stage Small Cell Lung Cancer (ES-SCLC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: PrE0510
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07057791
- Phase: 2
- Setting: Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
- Sponsor: PrECOG, LLC.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07057791: https://clinicaltrials.gov/study/NCT07057791

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07057791.json